Lupin today said that it has received final approval from the US health regulator to sell generic diabetes management drug Pioglitazone tablets in the American market.
Lupin said its US subsidiary, Lupin Pharmaceuticals Inc, has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market the generic version of Takeda Pharmaceuticals USA Inc’s Actos tablets.
The company said in a BSE filing that its subsidiary will shortly commence marketing the product. The approval has been granted for tablets in strengths of 15 mg, 30 mg and 45mg.
“Lupin’s Pioglitazone tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings,” the company said.
As per IMS MAT December data, Actos tablets had annual US sales of $236 million.
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…